FlandersBio on Twitter

Follow us on Twitter

Archive for February 2015 - News

Archive for February 2015 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Cardio3 BioSciences successfully completes a €32 Million private placement

27.02.2015

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announced it has raised approximately €32 million through a private placement of ordinary shares to investors in the United States and Europe. read more

Cardio3 BioSciences to raise capital via a private placement of new shares

26.02.2015

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, announces today the launch of a private placement of new ordinary shares to institutional investors. Cardio3 BioSciences intends to raise up to a maximum of 713,380 new shares (10% of the current share capital). read more

3D-PharmXchange celebrates its 5th anniversary!

26.02.2015

This year, 3D-PharmXchange celebrates its 5th anniversary. On February 1st 2010, 3D-PharmXchange started with three founders from an attic room. read more

TiGenix launches an offering of EUR 25 million convertible bonds

26.02.2015

TiGenix NV (Euronext Brussels: TIG; the "Company"), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, is launching the offering (the "Offering") of senior, unsecured convertible bonds due 2018 (the "Convertible Bonds"), for a principal amount of EUR 25 million and with a nominal value of EUR 100,000 per Convertible Bond. The Convertible Bonds will be convertible into fully paid ordinary shares of the Company (the "Shares"). The Convertible Bonds will be senior, unsecured obligations of TiGenix NV and guaranteed by TiGenix S.A.U. read more

ABLYNX ANNOUNCES 2014 FULL YEAR RESULTS

26.02.2015

Ablynx [Euronext Brussels: ABLX] today announced its consolidated results for 2014, which have been prepared in accordance with IFRS as adopted by the European Union. read more

MDxHealth Reports Fourth Quarter and Fiscal Year 2014 Results

26.02.2015

MDxHealth SA (Euronext: MDXH.BR), today announced results for the fourth quarter and the fiscal year ended December 31, 2014. read more

IPO Market still open?

25.02.2015

"The current interest for biotech stocks is the result by an increased enthusiasm of both retail and institutional investors in the sector, driven by cash inflows in the market seeking for stocks with substantial upside potential." Jan De Kerpel, KBC Securities read more

Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatment

23.02.2015

Galapagos NV (Euronext: GLPG), a clinical stage biotechnology company focused on developing novel mode of action medicines, announces that the last patient in the DARWIN 1 trial with filgotinib has completed the 12 week visit. This last patient's 12 week visit triggers the clinical research organization's process of final 12 week data collection from all 599 patients enrolled in the trial, to be followed by database lock and analysis. As this process takes approximately 7 to 8 weeks, Galapagos expects to announce topline results by mid-April 2015. read more

TiGenix: TiGenix's Phase III trial design for Cx601 endorsed by President-Elect of ECCO

23.02.2015

TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that Dr Julian Panés, a leading clinical specialist in inflammatory bowel disease, endorsed the design of the Company's Phase III trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease during his presentation last week at the 10th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) held in Barcelona, Spain. read more

Bone Therapeutics: Information on the total number of voting rights and shares

19.02.2015

BONE THERAPEUTICS, a leader in bone cell therapy addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, discloses the information required under article 15 of the law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print